Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • e-Health Research International Congress 2016

    Paris, France
    Oct11 – 12, 2016

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.

Comorbid Hypertension and Obesity among Patients with Type 2 Diabetes in Urban China Increases Healthcare Resource Use

Sep 4, 2012

New Results from the National Health and Wellness Survey Show Patients with Diabetes and Comorbid Hypertension and Obesity in Urban China Visit Their Doctors, Emergency Rooms More Often

NEW YORK, September 4, 2012—Chinese patients with type 2 diabetes with comorbid hypertension or comorbid hypertension plus obesity see their physicians, visit the emergency room and are hospitalized significantly more often than type 2 diabetics without these comorbidities, according to new findings from the National Health and Wellness Survey (NHWS), conducted by Kantar Health and presented today at the ISPOR (International Society for Pharmacoeconomic and Outcomes Research) 5th Asia-Pacific Conference.

“Past research has shown strong associations of hypertension and obesity with type 2 diabetes, especially in the US. Our research in urban China found that 44% of patients with type 2 diabetes have either one or both of these comorbidities, nearly half the rate as in the US,” says Marco DiBonaventura, Ph.D., Director, Health Economics and Outcomes Research, at Kantar Health. “However, those Chinese patients who do have concomitant hypertension or obesity exhibit a significant cost burden due to their increased use of healthcare resources, such as doctor visits and hospitalizations, made worse by the fact that the majority of Chinese patients have to pay for these resources out-of-pocket.”

Chinese patients with type 2 diabetes with comorbid hypertension and obesity and type 2 diabetes with comorbid hypertension had 6.26 and 4.96, respectively, visits to their doctor in the past six months, compared with 3.11 in patients with only type 2 diabetes. Likewise, type 2 diabetics with hypertension and obesity and type 2 diabetics with hypertension had significantly more ER visits (0.63 and 0.23, respectively) and hospitalizations (0.46 and 0.26, respectively) than type 2 diabetes-only patients (0.11 ER visits and 0.09 hospitalizations).

“Beyond the cost burden these patients face, the combined effect of comorbid hypertension and obesity is associated with incremental decrements in quality of life, both mental and physical,” Dr. DiBonaventura says. “Because lifestyles in China are becoming increasingly sedentary, greater attention should be given to the management of hypertension and obesity in this population.”

Visit Kantar Health’s website to download Dr. DiBonaventura’s white paper, “The Burden of the Complicated Type 2 Diabetes Patient in China.”     


About the National Health and Wellness Survey (NHWS)

The study’s results were drawn from the 2010 China NHWS, a nationally representative, self-administered survey conducted annually via the Internet. Topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.

Kantar Health conducts NHWS annually in the US, Europe, Asia and Latin America. The survey is the largest self-reported database in the healthcare industry.


About Kantar Health (

Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.


With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.


Contact Information

For more information on Kantar Health, please contact Paula Paradise, Vice President of Global Marketing, at or +1-484-442-1431.